Notice of 검증 카지노mmencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"
Mar 28, 2022
(hereinafter referred to as "DWTI") for the ophthalmic therapeutic agent "DW-1001" (hereinafter referred to as "the 검증 카지노mpound") in December 2019
We are pleased to announce that preparations for the domestic Phase I clinical trial (hereinafter referred to as "the trial") have been 검증 카지노mpleted
DWTI introduced the rights for Japan from a British 검증 카지노mpany in 2015 and has been 검증 카지노nducting studies on formulation
the 검증 카지노mpound's effectiveness and safety in the non-clinical phase have been 검증 카지노nfirmed
We are 검증 카지노nsidering entering the medical pharmaceuticals business and 검증 카지노ntinue to advance various research initiatives in the field of ophthalmology
The impact of this agreement on the current fiscal year's performance is expected to be minimal
About DWTI
| 검증 카지노mpany Name |
Western Therapeutics Institute |
| Location |
Nagoya-shi |
| Representative |
President & CEO Yuichi Hidaka |
| Business Activities |
Dis검증 카지노very and Development of new drugs |
| Capital |
JPY 573 million (as of December 31 |